How does 0M40's PB Ratio compare to its peers?

0M40 is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (12.8x).

How does 0M40's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?

0M40 is good value based on its Price-To-Book Ratio (2.3x) compared to the UK Pharmaceuticals industry average (2.7x).

What is 0M40's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0M40's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 0M40 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0M40 ($1.31) is trading below our estimate of [[fair value]] ($56.32)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is lower than the current share price.

Zynerba Pharmaceuticals (LSE:0M40) - Stock Price, News & Analysis

0M40 Stock Overview

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. More details

0M40 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 97.7% below our estimate of its fair value

Earnings are forecast to grow 67.21% per year

Earnings have grown 0.8% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months

Has less than 1 year of cash runway

Does not have a meaningful market cap ($66M)

+ 2 more risks

Zynerba Pharmaceuticals, Inc. Competitors

Redx Pharma

AIM:REDX

UK£58.3m

ECO Animal Health Group

AIM:EAH

UK£44.7m

Poolbeg Pharma

AIM:POLB

UK£38.8m

Sareum Holdings

AIM:SAR

UK£33.1m

Price History & Performance

Summary of all time highs, changes and price drops for Zynerba Pharmaceuticals
Historical stock prices
Current Share Price	US$1.31
52 Week High	US$1.40
52 Week Low	US$0.31
Beta	1.19
11 Month Change	-1.21%
3 Month Change	276.19%
1 Year Change	65.74%
33 Year Change	n/a
5 Year Change	-82.55%
Change since IPO	-89.19%

Recent updates

Shareholder Returns

	0M40	GB Pharmaceuticals	GB Market
7D	4.0%	5.0%	1.7%
1Y	65.7%	2.2%	8.3%

Return vs Industry: 0M40 exceeded the UK Pharmaceuticals industry which returned -7.1% over the past year.

Return vs Market: 0M40 exceeded the UK Market which returned -2.5% over the past year.

Price Volatility

Is 0M40's price volatile compared to industry and market?
0M40 volatility
0M40 Average Weekly Movement	89.3%
Pharmaceuticals Industry Average Movement	6.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0M40's share price has been volatile over the past 3 months.

Volatility Over Time: 0M40's weekly volatility has increased from 59% to 89% over the past year.

About the Company

Founded	Employees	CEO	Website
2007	26	Armando Anido	www.zynerba.com

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery.

Zynerba Pharmaceuticals, Inc. Fundamentals Summary

How do Zynerba Pharmaceuticals's earnings and revenue compare to its market cap?
0M40 fundamental statistics
Market cap	US$65.60m
Earnings (TTM)	-US$37.58m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Is 0M40 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0M40 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$37.58m
Earnings	-US$37.58m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.74
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 0M40 perform over the long term?

See historical performance and comparison

0M40 Stock Overview

Rewards

Risk Analysis

Zynerba Pharmaceuticals, Inc. Competitors

AIM:REDX

UK£58.3m

AIM:EAH

UK£44.7m

AIM:POLB

UK£38.8m

AIM:SAR

UK£33.1m

Price History & Performance

Recent News & Updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

New minor risk - Profitability

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Forecast to breakeven in 2025

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

Shareholder Returns

Price Volatility

About the Company

Zynerba Pharmaceuticals, Inc. Fundamentals Summary

0.0x

-1.7x

Earnings & Revenue